Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Video Interview: 'More Out-Licensing Divestment Expected In 2016,' Says AZ's Grady

This article was originally published in Scrip

Executive Summary

AstraZeneca PLC's head of strategic partnering and business development, Shaun Grady, tells Pharma Intelligence senior editor Sten Stovall that Britain's second-biggest drug maker remains committed to developing medicines across small molecules, biologics, vaccines, protein engineering and devices and that's what its future targeted business development strategy will pursue. AstraZeneca has recently been selling mature products to buyers in efforts to focus on its central activities while also unlocking value from medicines in its portfolio, a recent example being the sale in March of rights to opioid-induced constipation drug Moventig (naloxegol) in the EU, as well as Iceland, Norway, Switzerland and Lichtenstein to Kyowa Hakko Kirin subsidiary ProStrakan Group. Grady makes clear in this interview that "Where there are assets we feel are more valuable in the hands of others then we will look to partner them."

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register